Dragon Pharma announces sufficient votes based on receipt of preliminary proxies to approve Merger

Dragon Pharmaceutical Inc. ("Dragon" or the "Company" TSX: DDD; OTCBB: DRUG) announced that based on the receipt of preliminary proxies, the Company believes that it has sufficient votes to approve the Agreement and Plan of Merger ("Merger") by and among Dragon, Chief Respect Limited, Datong Investment Inc., a subsidiary of Chief Respect Limited, and Mr. Yanlin Han. The Merger must be approved by holders of a majority of the outstanding shares of the Company's voting common stock and a majority of the votes cast by the minority shareholders of outstanding shares of the Company's voting common stock excluding the votes cast by Mr. Han. If the Merger is approved, Datong Investment Inc. will merge with and into Dragon and each holder of Dragon shares of common stock, excluding Mr. Han, will receive $0.82 per share.

The receipt of preliminary proxies is not an official vote. Accordingly, shareholders are encouraged to vote prior to or at the Special Meeting of Shareholders of the Company to be held on Tuesday, July 20, 2010 at 10:30 a.m., Pacific Time at the Company's corporate office located at Suite 310, 650 West Georgia Street, Vancouver, British Columbia, Canada V6B 4N9, at which time the Company expects to finalize shareholder approval of the proposed Merger.